Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Nitric Oxide for Microvascular Dysfunction in Traumatic Brain Injury
NCT05616910Phase 2Enrolling by invitation
- Sponsor
- University of Pennsylvania
- Start
- Apr 2025
- Primary completion
- Mar 2028
- Modality
- Transdermal Patches, Inhalation Devices, Hydrogel Systems
- Countries
- 1
01
Overview
Phase 2, randomised trial of nitric oxide in traumatic brain injury (TBI) (2 arms), sponsored by University of Pennsylvania. Primary endpoint: Cerebral Metabolism assessed by Spectroscopy at 4 days. Started Apr 2025; status: enrolling by invitation.
02
Drugs
nitric oxide
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on NCT05616910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05616910.